Shots:
- The P-III (SANOVO) trial assessed Orpathys (300 or 200mg, BID) + Tagrisso (80mg, QD) vs Tagrisso in 326 treatment-naïvepts with locally advanced or metastatic NSCLC harboring EGFR mutations (exon 19 deletion or L858R) & MET overexpression
- The combination significantly improved PFS in both high-MET and ITT populations, while also showing encouraging OS benefit; follow-up is ongoing, with results to be presented at an upcoming medical meeting
- In China, Orpathys + Tagrisso is approved for EGFRm NSCLC with MET amplification after EGFR-TKI progression, based on P-III (SACHI) trial data
Ref: Globenewswire | Image: AstraZeneca & Hutchmed | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
